Bifendate inhibits autophagy at multiple steps and attenuates oleic acid-induced lipid accumulation

Biochem Biophys Res Commun. 2022 Nov 26:631:115-123. doi: 10.1016/j.bbrc.2022.09.067. Epub 2022 Sep 20.

Abstract

Some traditional Chinese medicines exert roles in the therapy of liver diseases by modulating autophagy. Bifendate (DDB), a synthetic intermediate of Schisandrin C extracted from Schisandrae chinensis, is clinically used to treat hepatitis in China. While DDB is a positive control to research some potential hepatoprotective agents, its related molecular mechanisms are unknown. In this study, we show that DDB inhibited autophagosome-lysosome fusion, lysosome acidification and autophagic lysosome reformation. Moreover, DDB attenuated oleic acid-induced lipid droplet accumulation. These findings reveal the effects of DDB on the autophagy-related processes and lysosomal function, and also provide a possibility to understand the bioactivity mechanism of DDB in the future.

Keywords: Autophagy; Bifendate; Lipid droplet; Lysosome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autophagy
  • Biphenyl Compounds
  • Hydrocarbons, Chlorinated* / pharmacology
  • Lysosomes
  • Oleic Acid* / pharmacology

Substances

  • Biphenyl Compounds
  • Hydrocarbons, Chlorinated
  • bifendate
  • Oleic Acid
  • DDB